

S 3385

A bill to prohibit contracting with certain biotechnology providers.

Congress: 118 (2023–2025, Ended)

Chamber: Senate

Policy Area: Government Operations and Politics

Introduced: Dec 4, 2023

Current Status: Read twice and referred to the Committee on Homeland Security and Governmental Affairs.

Latest Action: Read twice and referred to the Committee on Homeland Security and Governmental Affairs. (Dec 4, 2023)

Official Text: <https://www.congress.gov/bill/118th-congress/senate-bill/3385>

Sponsor

Name: Sen. Hagerty, Bill [R-TN]

Party: Republican • **State:** TN • **Chamber:** Senate

Cosponsors

No cosponsors are listed for this bill.

Committee Activity

Committee	Chamber	Activity	Date
Homeland Security and Governmental Affairs Committee	Senate	Referred To	Dec 4, 2023

Subjects & Policy Tags

Policy Area:

Government Operations and Politics

Related Bills

No related bills are listed.

This bill prohibits federal contracting with certain biotechnology providers connected to foreign adversaries, with exceptions.

Specifically, the bill prohibits executive agencies from (1) procuring, obtaining, extending, or renewing a contract to procure or obtain any biotechnology equipment or service produced or provided by a biotechnology company of concern; or (2) entering into a contract or extending or renewing a contract that uses such equipment or service or that will require the direct use of such equipment or services. Those agencies may not obligate or expend loan or grant funds for such purposes.

A *biotechnology company of concern* includes BGI Group, MGI Group, Complete Genomics, any subsidiary, parent affiliate, or successor of such entities, and any entity that

- is subject to the jurisdiction, direction, or control of a foreign adversary;
- operates primarily in the biotechnology industry; and
- the Department of Defense (DOD) deems to pose a risk to national security.

DOD must determine, within 90 days after this bill's enactment, whether WuXi AppTec, Axbio, and any subsidiary, affiliate, or successor of such entities, or any other entity headquartered in or organized under the laws of China, is a biotechnology company of concern.

Executive agencies may waive the prohibitions on a case-by-case basis under specified circumstances.

Actions Timeline

- **Dec 4, 2023:** Introduced in Senate
- **Dec 4, 2023:** Read twice and referred to the Committee on Homeland Security and Governmental Affairs.